S-1 · primary offering
Issued 2023
Proposed maximum
Shares registered
- Filed
- Effective
Sector: Services-Medical LaboratoriesIndustry: Industrial - DistributionCountry: MYExchange: Nasdaq
DilutionScan read 21 of BioNexus Gene Lab Corp's SEC filings and found 1 warrant series, 1 ATM program, 1 equity line, 1 shelf registration, 1 S-1 registration and 3 completed offerings on file for BGLC. The latest dilution event on file is ATM sales on Aug 14, 2026. Analysis updated Oct 21, 2026.
Raise routes on file: active ATM + effective shelf + active equity line · latest dilution event 81 days ago
The dominant contractual driver and its mechanism, then each further driver ranked.
Aug 14, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Shares outstanding, potential dilution and cash over time
Issued 2023
Proposed maximum
Shares registered
Shares Underlying
Exercise Price
Issued 2025
Total capacity
Sold to date
Issued 2025
Commitment
Sold to date
Issued 2025
Total capacity
Remaining
Issued 2025
Gross proceeds
Price per share
Issued 2025
Gross proceeds
Price per share
Gross proceeds
Price per share
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
DilutionScan ProEvery instrument in full · $59/mo
Covered companies in Industrial - Distribution, then the closest in size. All tickers A to Z